|
| Start-finish date | Intervention | Action | Design |
|
| HALT-ADPKD STUDY (NCT00283686) | 2006–2013 | ACE inhibitors and ARBs (singly or in combination) | Reduce the rate of increase in kidney volume and slow the decline in GFR | Multicenter, randomized, placebo controlled |
| NCT00428948 | 2007–2011 | V2 receptor antagonist (Tolvaptan) | Reduce the concentrations of cAMP and slow the progression of renal enlargement | Multicenter, double blind, placebo controlled |
| NCT00309283 | 2006–2010 | Long-acting somatostatin (octreotide) | Inhibit the growth of the polycystic kidneys and liver | Randomized Single Center, Single blind, Placebo controlled |
| NCT00426153 | 2007–2010 (open-label extention) | Long-acting somatostatin (octreotide) | Inhibit the growth of the polycystic kidneys and liver | Double blind, Randomized, Placebo controlled, Crossover |
| NCT00565097 | 2007–2009 (open-label extention) | Long-acting somatostatin (lanreotide) | Inhibit the growth of the polycystic kidneys and liver | Double blind, Randomized, Placebo controlled |
| Trials with target mTOR | — | mTOR inhibitors (sirolimus, everolimus) | Modulate disease progression and development of renal cysts | — |
|
